Previous close | 51.75 |
Open | 51.30 |
Bid | 51.44 x 100 |
Ask | 51.82 x 100 |
Day's range | 50.42 - 52.60 |
52-week range | 17.00 - 58.21 |
Volume | |
Avg. volume | 408,201 |
Market cap | 1.908B |
Beta (5Y monthly) | 1.22 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.41 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 62.71 |
ALISO VIEJO, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small con
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference. RxSight’s management is scheduled to participate in a fireside chat on Wednesday, April 10, 2024, at 12:45 p.m. Pacific Time / 3:45 p.m. Eastern Time. Interested parties may acces
RxSight, Inc. ( NASDAQ:RXST ) came out with its full-year results last week, and we wanted to see how the business is...